Quick Take
Black Diamond Therapeutics (BDTX) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The company is developing a platform that identifies small molecule kinase inhibitors, which help to slow or stop cancer.
BDTX is a very early stage biopharma with promising in vitro results for its lead candidate, but the deal is still extremely high-risk.
Company & Technology
Cambridge, Massachusetts-based Black Diamond was founded to create genetically derived solutions to a variety of cancer conditions through its MAP platform.
Management